liveBook · Manning

Drug-target affinity prediction

As explained in Build AI Drug Discovery Pipelines

Drug-target affinity prediction is the computational estimation of the strength of binding between a drug molecule and a biological target.

Drug-target affinity prediction estimates how strongly a drug molecule binds to a biological target. It supports virtual screening by helping researchers identify promising compounds from large chemical libraries, reducing the time and cost of drug development. section 11.1

Traditional structure-based methods such as molecular docking and molecular dynamics depend on known three-dimensional protein structures. Sequence-based virtual screening instead predicts affinity from a target’s amino acid sequence when structural information is unavailable. section 11.1

Affinity prediction has developed from interaction detection toward quantitative estimation:

  • Binary classification asks whether a drug-target pair binds or does not bind. section 11.1
  • Regression predicts a continuous affinity value, commonly based on experimental Kd, Ki, or IC50 measurements. section 11.1
  • Evaluation must account for dataset structure: mean squared error can favor the dominant weak-binding value, while Concordance Index evaluates whether affinity rankings are correct. section 11.1.1

DAVIS and KIBA benchmarks

DAVIS contains a sharp value-5 spike caused by an assay detection limit, aggregating weak and non-binding pairs. KIBA integrates heterogeneous Kd, Ki, and IC50 measurements into a more consistent bioactivity dataset with a more continuous target distribution. section 11.1.1

Figure 11.2 Distribution of pKd Affinity Values in the DAVIS Dataset and KIBA scores in the KIBA Dataset. For the DAVIS dataset, we observe a very large, sharp peak visible at the y-value of 5, with a much smaller, broader distribution of values between 6 and 10.

Compare the sharply concentrated DAVIS pKd distribution with the broader KIBA score distribution to see why dataset characteristics affect evaluation. section 11.1.1

How Build AI Drug Discovery Pipelines covers it

How deep it goes
Explains classification, regression, structural constraints, and dataset artifacts, but stops short of model implementation.
Examples
Uses DAVIS and KIBA benchmarks, including their contrasting affinity distributions and measurement challenges.
What you can do after
Evaluate models with rank-sensitive Concordance Index when skewed labels can make mean squared error misleading.
How it connects
Connects virtual screening with protein structure, amino acid sequences, molecular docking, molecular dynamics, and regression.

Related concepts

This explainer was generated by Manning's knowledge graph from the text of Build AI Drug Discovery Pipelines. The section links point to the parts of the book it draws on.